Discovery of selective Mdm2-inhibiting peptides maps a pathway to exploitation of the target May 29, 2020
Synthetic Biologics enters exclusive option to license intellectual property for use of SYN-020 May 29, 2020
FDA clears initiation of phase II study of PB-1046 for hospitalized patients with COVID-19 May 28, 2020
RSS